Advertisement
Screener

Aquestive Therapeutics, Inc. (AQST) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Aquestive Therapeutics, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Aquestive Therapeutics, Inc. return tang equity for the quarter ending 2026-06-30 was 138.24%, a 54.29% increase year-over-year.
  • Aquestive Therapeutics, Inc. return tang equity for the quarter ending 2026-03-31 was 202.36%, a 127.32% increase year-over-year.
  • Aquestive Therapeutics, Inc. return tang equity for the quarter ending 2025-12-31 was 248.90%, a 239.23% increase year-over-year.
  • Aquestive Therapeutics, Inc. return tang equity for the quarter ending 2025-09-30 was 1678.73%, a 2066.56% increase year-over-year.
  • Aquestive Therapeutics, Inc. return tang equity for fiscal 2025 was 248.90%, a 239.23% increase from fiscal 2024.
  • Aquestive Therapeutics, Inc. return tang equity for fiscal 2024 was 73.37%, a 904.68% increase from fiscal 2023.
  • Aquestive Therapeutics, Inc. return tang equity for fiscal 2023 was 7.30%, a 83.90% decline from fiscal 2022.
  • Aquestive Therapeutics, Inc. return tang equity for fiscal 2022 was 45.35%, a 47.17% decline from fiscal 2021.
Available history
2017-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30138.24%-$78.23M-$56.59M
2026-03-31202.36%-$68.91M-$34.05M
2025-12-31248.90%-$83.78M-$33.66M
2025-09-301678.73%-$68.98M-$4.11M
2025-06-3089.60%-$65.04M-$72.59M
2025-03-3189.02%-$54.24M-$60.93M
2024-12-3173.37%-$44.14M-$60.16M
2024-09-3077.48%-$35.19M-$45.42M
2024-06-3072.49%-$25.72M-$35.48M
2024-03-3176.63%-$28.77M-$37.54M
2023-12-317.30%-$7.87M-$107.77M
2023-09-3011.62%-$12.11M-$104.24M
2023-06-3020.94%-$22.61M-$108.01M
2023-03-3129.94%-$33.12M-$110.63M
2022-12-3145.35%-$54.41M-$119.99M
2022-09-3064.96%-$71M-$109.31M
2022-06-3075.76%-$73.02M-$96.38M
2022-03-3174.14%-$69.09M-$93.18M
2021-12-3185.83%-$70.54M-$82.19M
2021-09-30102.57%-$61.96M-$60.41M
2021-06-30118.78%-$63.96M-$53.85M
2021-03-31103.93%-$53.93M-$51.89M
2020-12-31114.78%-$55.78M-$48.6M
2020-09-30131.17%-$48.05M-$36.63M
2020-06-30231.99%-$49.91M-$21.52M
2020-03-31324.53%-$68.05M-$20.97M
2019-12-311055.71%-$66.25M-$6.28M
2019-09-30195.11%-$67.55M-$34.62M
2019-06-30258.43%-$64.18M-$24.84M
2019-03-311283.83%-$80.2M-$6.25M
2018-12-31-621.47%-$61.38M$9.88M
2018-09-30-247.43%-$57.47M$23.23M
2018-06-3086.74%-$33.98M-$39.18M
2018-03-3114.95%-$3.39M-$22.65M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31248.90%-$83.78M-$33.66M
2024-12-3173.37%-$44.14M-$60.16M
2023-12-317.30%-$7.87M-$107.77M
2022-12-3145.35%-$54.41M-$119.99M
2021-12-3185.83%-$70.54M-$82.19M
2020-12-31114.78%-$55.78M-$48.6M
2019-12-311055.71%-$66.25M-$6.28M
2018-12-31-621.47%-$61.38M$9.88M
2017-12-3133.43%-$8.94M-$26.75M

Similar stocks

Stock NameCountryMarket CapPE Ratio
CorMedix Inc. (CRMD)United States$0.605B3.25
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Monopar Therapeutics (MNPR)United States$0.598B-34.82
Altimmune, Inc. (ALT)United States$0.593B-6.43
Neurogene Inc. (NGNE)$0.625B-4.46
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61